Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review

被引:1
|
作者
Kachmazov, Andrei [1 ]
Bolotina, Larisa [1 ]
Kornietskaya, Anna [1 ]
Kuznetsova, Olesya [2 ,3 ]
Ivanov, Maxim [3 ]
Fedenko, Alexander [1 ]
机构
[1] Minist Hlth Russian Federat, P Hertsen Moscow Oncol Clin Res Inst, Branch Natl Med Res Radiol Ctr, Moscow, Russia
[2] NN Blokhin Natl Med Res Ctr Oncol Minist Hlth Russ, Fed State Budgetary Inst, Moscow, Russia
[3] Atlas Oncodiagnost LLC, RnD Dept, Moscow, Russia
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
pancreatic cancer; PDAC; talazoparib; PARP inhibitors; PARPi; PALB2; molecular profiling; precision oncology; CANCER; GEMCITABINE; TRIAL;
D O I
10.3389/fonc.2022.953908
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various homologous repair pathway alterations remains mostly undetermined. Here we report a clinical case of a 56-year-old woman with pancreatic ductal adenocarcinoma harboring a somatic PALB2 mutation. Following disease progression after 10 cycles of FOLFIRINOX chemotherapy and two cycles of second-line gemcitabine, she was switched to talazoparib and achieved a complete clinical response after 25 months of treatment. The patient remains alive without clinical or radiological signs of disease progression three years after the start of talazoparib with no targeted therapy-related toxicities. This case highlights the role of broad molecular profiling as a window of opportunity to achieve a durable response for selected pancreatic cancer patients while pinpointing our gaps in understanding the whole picture of management of these patients since a new puzzle element represented by PARP inhibitors was introduced to clinical practice.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature
    Valeri, S.
    Borzomati, D.
    Nappo, G.
    Perrone, G.
    Santini, D.
    Coppola, R.
    PANCREATOLOGY, 2014, 14 (05) : 425 - 430
  • [22] Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature
    Shi, Yuequan
    Wang, Mengzhao
    THORACIC CANCER, 2018, 9 (12) : 1788 - 1794
  • [23] Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review
    Argentiero, Antonella
    Calabrese, Angela
    Solimando, Antonio Giovanni
    Notaristefano, Antonio
    Panarelli, Marzia M. G.
    Brunetti, Oronzo
    CLINICAL CASE REPORTS, 2019, 7 (10): : 1972 - 1976
  • [24] Case report & review: Bilateral NIFTP harboring concomitant HRAS and KRAS mutation: Report of an unusual case and literature review
    Brogna, Marianna Rita
    Collina, Francesca
    Chiofalo, Maria Grazia
    De Bartolo, Debora
    Montone, Angela
    Schiano, Maria Rosaria
    Del Sesto, Michele
    Pizza, Nubia
    Ferrara, Gerardo
    MOLECULAR CARCINOGENESIS, 2024, 63 (12) : 2273 - 2281
  • [25] Pancreatic adenocarcinoma with early esophageal metastasis: A case report and review of literature
    Burns, Ethan Alexander
    Kasparian, Saro
    Khan, Usman
    Abdelrahim, Maen
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2020, 11 (02): : 83 - 90
  • [26] Pancreatic Ductal Adenocarcinoma with Autoimmune Pancreatitis: A Case Report and Literature Review
    Sakurai, Yusuke
    Yokoyama, Kensuke
    Kanno, Atsushi
    Tanaka, Akitsugu
    Ikeda, Eriko
    Ando, Kozue
    Taguchi, Masanobu
    Sasanuma, Hideki
    Sata, Naohiro
    Sano, Naoki
    Fukushima, Noriyoshi
    Yamamoto, Hironori
    INTERNAL MEDICINE, 2024,
  • [27] Malignant struma ovarii harboring a unique NRAS mutation: case report and review of the literature
    Gobitti, Carlo
    Sindoni, Alessandro
    Bampo, Chiara
    Baresic, Tanja
    Giorda, Giorgio
    Alessandrini, Lara
    Canzonieri, Vincenzo
    Franchin, Giovanni
    Borsatti, Eugenio
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2017, 16 (03): : 322 - 327
  • [28] Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
    Xu, Huanhuan
    Liang, Qi
    Xu, Xian
    Tan, Shanyue
    Wang, Sumeng
    Liu, Yiqian
    Liu, Lingxiang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [29] Intrasplenic Pancreatic Pseudocyst after Chemoradiation of a Pancreatic Adenocarcinoma Mimicking Progressive Disease: A Case Report and Review of the Literature
    Benter, Thomas
    Roehr, Oliver
    Moser, Lutz
    Kiewe, Philipp
    Hentschel, Leopold
    Platzek, Ivan
    Schuler, Markus K.
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2019, 2019
  • [30] Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature
    Sheng, Jin
    Pan, Hongming
    Han, Weidong
    FRONTIERS IN IMMUNOLOGY, 2023, 14